Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

849 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Validation of five prognostic models treated with axitinib beyond first-line nivolumab plus ipilimumab therapy for metastatic renal cell carcinoma: a Japanese multicenter retrospective study.
Kikuchi H, Osawa T, Matsushita Y, Kojima T, Sazuka T, Hatakeyama S, Goto K, Numakura K, Yamana K, Kandori S, Ueda K, Tanaka H, Kurahashi T, Bando Y, Kimura T, Nishiyama N, Kato T, Hara H, Ito Y, Kitamura H, Miyake H, Shinohara N. Kikuchi H, et al. Among authors: shinohara n. Jpn J Clin Oncol. 2025 Feb 2:hyaf018. doi: 10.1093/jjco/hyaf018. Online ahead of print. Jpn J Clin Oncol. 2025. PMID: 39893579
Surgical skill analysis focused on tissue traction in laparoscopic wet lab training.
Ebina K, Abe T, Higuchi M, Hotta K, Furumido J, Iwahara N, Senoo T, Komizunai S, Tsujita T, Sase K, Chen X, Kurashima Y, Kikuchi H, Miyata H, Matsumoto R, Osawa T, Murai S, Konno A, Shinohara N. Ebina K, et al. Among authors: shinohara n. Surg Open Sci. 2024 Aug 22;21:7-13. doi: 10.1016/j.sopen.2024.08.002. eCollection 2024 Sep. Surg Open Sci. 2024. PMID: 39677833 Free PMC article.
Real-world outcomes of avelumab plus axitinib in patients with advanced renal cell carcinoma in Japan: long-term follow-up from the J-DART2 retrospective study.
Kato T, Furukawa J, Hinata N, Ueda K, Hara I, Hongo F, Mizuno R, Okamoto T, Okuno H, Ito T, Kajita M, Oya M, Tomita Y, Shinohara N, Eto M, Uemura H. Kato T, et al. Among authors: shinohara n. Int J Clin Oncol. 2025 Jan;30(1):99-109. doi: 10.1007/s10147-024-02618-9. Epub 2024 Nov 16. Int J Clin Oncol. 2025. PMID: 39549218 Free PMC article.
Establishment of potent TCR-T cells specific for cisplatin-resistance related tumor-associated antigen, CLSPN using codon-optimization.
Hori K, Yamada S, Murata K, Miyata H, Mizue Y, Murai A, Minowa T, Sasaki K, Shijubou N, Kubo T, Morita R, Tokita S, Kanaseki T, Tsukahara T, Abe T, Shinohara N, Hirohashi Y, Torigoe T. Hori K, et al. Among authors: shinohara n. Hum Vaccin Immunother. 2024 Dec 31;20(1):2414542. doi: 10.1080/21645515.2024.2414542. Epub 2024 Nov 13. Hum Vaccin Immunother. 2024. PMID: 39539024 Free PMC article.
849 results